Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BxC-I17e in moderate to severe atopic dermatitis
NCT06055374Phase 1Withdrawn
- Sponsor
- Brexogen
- Start
- May 2024
- Primary completion
- Apr 2025
- Modality
- Liposomes, Cell Therapies
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing BxC-I17e with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events at Week 26. Planned start May 2024; status: withdrawn.
02
Drugs
BRE-AD01
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06055374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055374.